Role of a spray-type anti-adhesion barrier (AdSpray®) in post-operative outcomes following robot-assisted radical cystectomy for bladder cancer
Bladder · 2026
DOI: 10.14440/bladder.0281 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bladder, 2026. Verfasst von Yuki Oda und 10 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite advances in robot-assisted radical cystectomy (RARC) for bladder cancer and enhanced recovery protocols, post-operative gastrointestinal complications—particularly ileus and bowel obstruction—remain a significant clinical problem.
Objective
We investigated whether intraoperative AdSpray® (TERUMO) during RARC is associated with fewer post-operative complications and improved recovery, with a focus on gastrointestinal events.
Methods
We retrospectively reviewed consecutive patients who underwent RARC with urinary diversion at a single tertiary hospital between June 2019 and March 2025. The primary endpoint was any post-operative complication within 90 days. Prespecified gastrointestinal complications included paralytic ileus, intestinal obstruction, anastomotic leak, and anastomotic stricture. Additional outcomes were time to first liquid intake, time to resumption of a normal diet, and time to discharge. Intestinal obstruction was defined as a computed tomography-demonstrated transition point with compatible clinical findings, and paralytic ileus as radiographic ileus without obstruction. One-to-one propensity score matching (PSM) was used to balance baseline characteristics between the AdSpray and non-AdSpray groups. Post-matching logistic regression was used to estimate associations with binary outcomes, and time-to-event outcomes were analyzed using Kaplan–Meier methods.
Results
Among 71 patients, 17 (24%) received AdSpray, and 54 (76%) did not; PSM yielded two comparable cohorts (n = 17 each). AdSpray use was significantly associated with a lower 90-day incidence of intestinal obstruction in the matched cohorts (odds ratio = 0.15, 95% confidence interval = 0.02–0.88, p = 0.032). Times to resumption of oral intake and discharge were similar between groups (before PSM, log-rank p = 0.64; after PSM, log-rank p = 0.42).
Conclusion
These retrospective findings are hypothesis-generating and suggest that intraoperative AdSpray use during RARC may be associated with a reduced 90-day incidence of intestinal obstruction; however, they should not be interpreted as definitive evidence of a causal relationship.
Zitieren
APA
Oda, Y., Miyake, M., Miyamoto, T., Shimizu, T., Tomizawa, M., Hori, S., Morizawa, Y., Gotoh, D., Nakai, Y., Tanaka, N., & Fujimoto, K. (2026). Role of a spray-type anti-adhesion barrier (AdSpray®) in post-operative outcomes following robot-assisted radical cystectomy for bladder cancer. Bladder. https://doi.org/10.14440/bladder.0281
Vancouver
Oda Y, Miyake M, Miyamoto T, Shimizu T, Tomizawa M, Hori S, et al. Role of a spray-type anti-adhesion barrier (AdSpray®) in post-operative outcomes following robot-assisted radical cystectomy for bladder cancer. Bladder. 2026. doi:10.14440/bladder.0281
BibTeX
@article{Oda2026,
author = {Oda, Yuki and Miyake, Makito and Miyamoto, Tatsuki and Shimizu, Takuto and Tomizawa, Mitsuru and Hori, Shunta and Morizawa, Yosuke and Gotoh, Daisuke and Nakai, Yasushi and Tanaka, Nobumichi and Fujimoto, Kiyohide},
title = {Role of a spray-type anti-adhesion barrier (AdSpray®) in post-operative outcomes following robot-assisted radical cystectomy for bladder cancer},
journal = {Bladder},
year = {2026},
doi = {10.14440/bladder.0281}
}
EUVIMED